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The X-chromosome-linked inhibitor of apoptosis protein (XIAP) is a
multidomain protein whose main function is to block apoptosis by caspase
inhibition. XIAP is also involved in other signalling pathways, including NF-B
activation and copper homeostasis. XIAP is overexpressed in tumours,
potentiating cell survival and resistance to chemotherapeutics, and has therefore
become an important target for the treatment of malignancy. Despite the fact
that the structure of each single domain is known, the conformation of the full-
length protein has never been determined. Here, the first structural model of the
full-length XIAP dimer, determined by an integrated approach using nuclear
magnetic resonance, small-angle X-ray scattering and electron paramagnetic
resonance data, is presented. It is shown that XIAP adopts a compact and
relatively rigid conformation, implying that the spatial arrangement of its
domains must be taken into account when studying the interactions with its
physiological partners and in developing effective inhibitors.
1. Introduction
The X-chromosome-linked inhibitor of apoptosis protein
(XIAP) is a 497-residue cytoplasmic zinc-binding protein that
is expressed in most human tissues (Liston et al., 1996; The
Human Protein Atlas; https://www.proteinatlas.org/). XIAP
contains three zinc-binding baculovirus IAP repeat (BIR)
domains in the N-terminal region, a ubiquitin-associated
(UBA) domain and a C-terminal, zinc-binding Really Inter-
esting New Gene (RING) domain (Mace et al., 2010).
XIAP belongs to the IAP family, and was first recognized as
a potent inhibitor of apoptosis, directly blocking the proteo-
lytic activity of caspases (Deveraux et al., 1997; Eckelman et
al., 2006). Specifically, XIAP binds and inhibits the effector
caspases 3 and 7 through its BIR2 domain and a portion of the
linker between BIR1 and BIR2 (Sun et al., 1999; Riedl et al.,
2001; Chai et al., 2001), while it inhibits the initiating caspase 9
through its BIR3 domain (Srinivasula et al., 2001). XIAP is
overexpressed in tumours, where it potentiates cell survival
and resistance to chemotherapeutics owing to its anti-
apoptotic activity. Thus, XIAP has become an important target
for the development of cancer treatments aimed at antag-
onizing its interaction with caspases (Schimmer et al., 2006;
Nakagawa et al., 2006; Mizutani et al., 2007; Lopes et al., 2007;
Mannhold et al., 2010; Fulda & Vucic, 2012; Baggio et al.,
2018).
XIAP is also involved in other important cellular processes.
Through its BIR1 domain, XIAP is involved in the activation
of the NF-B transcription factor (Lu et al., 2007). The
C-terminal RING domain has E3 ubiquitin ligase activity
(Nakatani et al., 2013) that is responsible for the ubiquitin-
ation of several substrates such as RIP1 and RIP2, which are
involved in the pro-inflammatory TNF and NOD2 signalling
pathways, respectively (Krieg et al., 2009; Witt & Vucic, 2017;
Goncharov et al., 2018). Consequently, mutations in the XIAP
gene have been related to inflammatory diseases such as
X-linked lymphoproliferative syndrome type 2 (XLP2;
Damgaard et al., 2013) and inflammatory bowel disease (IBD;
Pedersen et al., 2014). Finally, the literature reports that XIAP
plays an important role in maintenance of intracellular copper
homeostasis and that its downregulation contributes to the
onset of copper toxicosis, such as in Wilson’s disease (Mufti et
al., 2006; Galba´n & Duckett, 2010).
The multifunctional roles of XIAP have raised several
questions about how this protein is able to perform so many
functions and which are the structural features that allow
XIAP to engage in so many interactions. Indeed, all of these
processes imply that XIAP constantly interacts with one or
more different partners in the cell, and the spatial arrange-
ment of its domains could differently modulate the various
interactions. The structures of all of the single domains of
XIAP have been characterized (Sun et al., 1999; Liu et al.,
2000; Lu et al., 2007; Tse et al., 2011; Lukacs et al., 2013;
Nakatani et al., 2013). XIAP contains five zinc fingers, one in
each BIR domain and two in the C-terminal RING domain
(Sun et al., 1999; Liu et al., 2000; Nakatani et al., 2013; Hou et
al., 2017), and it has been demonstrated that the BIR1 and the
RING domains form homodimers (Lu et al., 2007; Nakatani et
al., 2013; Hou et al., 2017). Despite the wealth of data available
for the single domains, there is no information about their
spatial arrangement, as the conformation of full-length XIAP
has never been determined. Consequently, structural char-
acterization of the full-length protein is essential in order to
elucidate the relation between its structural features and the
numerous cellular processes and interactions in which this
protein is involved. In this study, we employed an integrative
approach using data obtained by nuclear magnetic resonance
(NMR), small-angle X-ray scattering (SAXS) and electron
paramagnetic resonance (EPR) as energy restraints in
HADDOCK. The obtained models provide the first insight
into the spatial arrangement adopted by full-length XIAP in
solution.
2. Materials and methods
2.1. Protein expression and purification
The gene encoding XIAP was cloned in the pENTR vector
to use the Gateway cloning technology and was subcloned in
the pDEST-HisMBP vector (which adds a His tag followed by
maltose-binding protein at the N-terminus of the protein),
utilizing the pENTR/TEV/D-TOPO cloning kit (Invitrogen).
Escherichia coli BL21-CodonPlus (DE3)-RIPL cells were
transformed with the plasmid pDEST-HisMBP-XIAP and
grown in LB medium (or 15N M9 medium) supplemented with
100 mM ZnSO4 at 37C and 170 rev min
1. At mid-log phase,
the cells were induced with 0.75 mM IPTG and then grown
overnight at 18C and 170 rev min1. The cells were harvested
and resuspended in 100 ml binding buffer (20 mM Tris, 1 mM
TCEP, 5 mM imidazole pH 8) supplemented with protease-
inhibitor tablets (Bayer) and lysed by sonication (10 s on and
50 s off at 60% amplitude for 40 min). The lysate was passed
through a 5 ml HisTrap FF affinity column (GE Healthcare
Life Sciences) and washed with elution buffer (20 mM Tris,
1 mM TCEP, 500 mM imidazole pH 8). The His-MBP tag was
cleaved by overnight incubation with TEV with dialysis (5 l).
As a final purification step, gel filtration using a HiLoad 16/600
Superdex 200 pg column (GE Healthcare Life Sciences) was
performed in order to separate XIAP from the His-MBP tag
and to transfer the protein into the final buffer (20 mM Tris,
0.5 mM TCEP pH 7.4). The eluted fractions were checked by
SDS–PAGE (Supplementary Fig. S1) and those containing
pure XIAP were collected and concentrated using an Amicon
Ultra centrifugal filter device (50 kDa molecular-weight
cutoff).
2.2. NMR
NMR spectra were acquired at 310 K on a 700 MHz Bruker
Avance Neo spectrometer equipped with a TCI CryoProbe.
2D 1H–15N HSQC data were obtained from a sample of 15N-
XIAP (160 mMmonomer concentration) in 20 mM Tris buffer,
0.5 mM TCEP pH 7.4. The spectra were processed using
TopSpin from Bruker.
2.3. SEC-MALS
Size-exclusion chromatography combined with multi-angle
light scattering (SEC-MALS) was performed on full-length
XIAP (30 mM) utilizing a Superdex 200 10/300 GL column
(GE Healthcare Life Sciences) at a flow rate of 0.3 ml min1.
The instrumentation included multi-angle light scattering with
a quasi-elastic light-scattering detector and a refractometer
with extended range (Wyatt Technology) connected to a high-
performance liquid-chromatography (HPLC) system.
2.4. CD
Circular-dichroism experiments were performed on 2.2 mM
samples of full-length XIAP using a JASCO J-810 spectro-
meter. The spectra were processed with the JASCO Spectra
Manager software suite by applying a nine-point smoothing
function. Secondary-structure calculation was performed
using the BeStSel (Beta Structure Selection) web tool
(Micsonai et al., 2018).
2.5. ICP-AES
The zinc:protein ratio of full-length XIAP (5 mM) was
determined by inductively coupled plasma atomic emission
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spectrometry (ICP-AES) measurements carried out by a
Varian 720 ES simultaneous ICP-AES equipped with a
CETAC U5000 AT+ ultrasonic nebulizer.
2.6. Small-angle X-ray scattering
Synchrotron-radiation X-ray scattering from full-length
XIAP in solution was collected on the EMBL P12 beamline
at the PETRA III storage ring, DESY, Hamburg, Germany
(Blanchet et al., 2015). Images were recorded using a photon-
counting PILATUS 2M detector at a sample-to-detector
distance of 3.1 m and a wavelength () of 1.2 A˚, covering the
momentum-transfer range 0.01 < s < 0.5 A˚1, with s = 4sin/,
where 2 is the scattering angle. To obtain data from a
monodisperse sample, a size-exclusion chromatography
column was directly coupled to the scattering experiment
(SEC-SAXS). Here, the eluent from a Superdex 200 10/300
GL column (GE Healthcare Life Sciences) was passed
through a UV cell (280 nm, Agilent) and then to the SAXS
capillary, where 1 s sample exposures were recorded. 20 mM
Tris, 0.5 mM TCEP pH 7.4 was used as the mobile phase for
SEC. 100 ml of the purified sample (7.5 mg ml1) was injected
and the flow rate was 0.5 ml min1. SAXS data were recorded
from macromolecule-free fractions corresponding to the
matched solvent blank (frames 1389–1804 s) which eluted
directly after the peak corresponding to the separated XIAP
dimers (elution time maximum = 20.7 min, 10.4 ml; frames
1244–1281 s). Data reduction to produce the final scattering
profile of dimeric full-length XIAP was performed using
standard methods. Briefly, 2D-to-1D radial averaging was
performed using the SASFLOW pipeline (Franke et al., 2017).
CHROMIXS was used for the visualization and reduction of
the SEC-SAXS data sets (Panjkovich & Svergun, 2018). Aided
by the integrated prediction algorithms in CHROMIXS, the
optimal frames within the elution peak and the buffer regions
were selected. Single buffer frames were then subtracted from
sample frames one by one, scaled and averaged to produce the
final subtracted curve.
The indirect inverse Fourier transform of the SAXS data
and the corresponding probable real-space scattering pair
distance distribution [p(r) versus r profile] of full-length XIAP
was calculated using GNOM (Svergun, 1992), from which the
Rg and Dmax were determined. The p(r) versus r profile was
also used for volume and subsequent molecular-weight esti-
mates of the XIAP dimers, as evaluated by the DATPOROD
(Porod volume; Franke et al., 2017), DATMOW (Fischer et al.,
2010) and DATVC (Rambo & Tainer, 2013) modules of the
ATSAS 2.8 package. Ab initio bead modelling of XIAP was
performed using ten independent runs of DAMMIF (Franke
& Svergun, 2009); from this, the most probable model was
selected for further analysis by DAMAVER (Volkov &
Svergun, 2003). The ab initio modelling was performed with
and without symmetry constraints (P2 symmetry to reflect the
dimeric state of the protein). The resolution of the model
ensemble was estimated with SASRES (Tuukkanen et al.,
2016). The a priori shape classification of the SAXS data was
conducted with DATCLASS (Franke et al., 2018). The
molecular mass (MM) was evaluated based on concentration-
independent methods as described in Hajizadeh et al. (2018).
The SAXS data (as summarized in Supplementary Table
S2) and ab initio bead models, as well as the rigid-body
reconstruction of full-length XIAP, have been deposited in the
Small-Angle Scattering Biological Data Bank (SASBDB;
Valentini et al., 2015) under accession code SASDF24.
2.7. EPR
In order to perform EPR and EPR-DEER experiments, the
MTSL [S-(1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-
3-yl)methyl methanesulfonothioate] nitroxide spin label was
selected for site-directed spin labelling (SDSL; Hubbell et al.,
2013; Klare, 2013). WT XIAP possesses four cysteine residues
(Cys12, Cys202, Cys213 and Cys351) that are not involved in
zinc coordination. Given the homodimeric nature of XIAP,
labelling the same cysteine residue on each monomer would
provide a symmetrical distance restraint. Mutations were
sequentially introduced into the WT XIAP gene using the
QuikChange II mutagenesis kit (Invitrogen), and the resulting
genes were checked by DNA sequencing. Two triple mutants
of XIAP were chosen for the SDSL reaction, termed XIAP
C202 (i.e. XIAP C12A, C213G, C351S) and XIAP C351 (i.e.
XIAP C12A, C202S, C213G).
The SDSL reaction was performed by incubating the XIAP
mutants with a tenfold excess of MTSL. The reaction was kept
for 2 h at room temperature under continuous agitation, after
which an identical amount of MTSL was added to the solution
to improve the labelling yield. After 4 h, unreacted spin label
was eliminated by washing the reaction solution several times
with 20 mM Tris pH 7.4 buffer using an Amicon Ultra
centrifugal filter device (50 kDa molecular-weight cutoff). The
resulting samples were checked by X-band EPR to ensure
complete MTSL removal and to calculate the relative spin
concentrations from double integration of the signals. Using a
calibration curve, the total spin concentrations were 30 and
55 mM for the two XIAP mutants labelled with MTSL nitr-
oxide on Cys202 (XIAP C202R1, dimer concentration 15 mM)
and Cys351 (XIAP C351R1, dimer concentration 25 mM),
respectively, indicating an almost complete labelling reaction.
X-band (9.8 GHz) continuous-wave EPR (CW-EPR) experi-
ments were performed at room temperature on a Bruker
ELEXSYS E580 spectrometer. The parameters used were as
follows: microwave power = 10 mW, magnetic field modula-
tion amplitude = 0.1 mT, field sweep = 10 mT, receiver gain =
60 dB. The spectra were accumulated nine times to increase
the signal-to-noise ratio. Simulations were performed with the
SimLabel program (a GUI for the EasySpin software; Etienne
et al., 2017) to obtain the components of the experimental
spectra and the relative parameters (g-tensor, A splitting
constants and C correlation times).
Q-band experiments were performed on the same samples
analysed using CW-EPR with the standard EN5107D2 reso-
nator and an Oxford helium system to keep the temperature at
50 K. Four-pulse DEER experiments (34 GHz) were recorded
with a Hahn-echo pulse sequence /2––––echo with
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 = 40 ns (/2 = 20 ns) and 1 = 200 ns; 2 was set according to
the relative spin–spin relaxation time. The pump ELDOR
pulse was centred at the central resonance and the observed
frequency was set with an offset of 56 MHz. The total acqui-
sition time was 20–24 h to increase the signal-to-noise ratio.
All DEER measurements were performed with an eight-step
nuclear modulation average.
The DeerAnalysis2016 software was used to correct for
background echo decay involving a second-order polynomial
baseline correction, and successively to obtain the relative
distance distribution (Jeschke, 2002, 2012). For the XIAP
C202R1 sample, the fitted curve on the echo oscillation had an
r.m.s. value of 0.017, while for the XIAP C351R1 sample the
uncertainty could not be calculated owing to the absence of
echo decay.
2.8. Ensemble analysis
In Ensemble Optimization Modelling (EOM) analysis,
ensembles of models with variable conformations are selected
from a large pool of randomly generated models such that the
scattering from the ensemble fits the experimental data, and
the distributions of the overall parameters (e.g. Rg and Dmax)
in the selected pool are compared with the original pool (Tria
et al., 2015). For the preliminary EOM analysis, 14 000 models
with randomized linkers were generated based on the atomic
structures from the individual domains: BIR1 (PDB entry
2poi; Lu et al., 2007), BIR2 (PDB entry 4j3y; Lukacs et al.,
2013), BIR3 (PDB entry 4kmp; X. Li, J. Wang, S. M. Condon &
Y. Shi, unpublished work), UBA (PDB entry 2kna; Hui et al.,
2010) and RING (PDB entry 4ic2; Nakatani et al., 2013). The
missing linker residues (217 in total) as well as 21 N-terminal
residues make up 23% of the overall sequence. To account
for the dimerization, P2 symmetry was partially applied by
constraining the BIR1 as well as the RING dimer interfaces as
seen in the crystal structure (PDB entries 2poi and 4ic2).
2.9. HADDOCK modelling
The input model for HADDOCK (Dominguez et al., 2003;
van Zundert et al., 2016) was generated starting from the
atomic structures of the individual domains: BIR1 (PDB entry
2poi), BIR2 (PDB entry 1i3o; Riedl et al., 2001), BIR3 (PDB
entry 5m6e; Tamanini et al., 2017), UBA (PDB entry 2kna)
and RING (PDB entry 5o6t; Gabrielsen et al., 2017). These
structures were chosen to maximize the number of structurally
defined segments. The domains were arranged in an extended,
O-shaped configuration (Supplementary Fig. S3) using
PyMOL v.1.4 (Schro¨dinger). The dimeric interfaces of BIR1
and RING were maintained as in the experimental structures.
All of the unstructured residues were removed from the
starting model and were subsequently reintroduced as
extended loops, with the exception of the N-terminal 22 resi-
dues. In order to reconstruct the unstructured loops, an
XPLOR-NIH (Schwieters et al., 2003, 2006) protocol was
used, in which the structured parts were kept fixed and the
Figure 1
XIAP is a compact homodimer in solution. (a) Experimental CD spectrum (black) of full-length XIAP (2.2 mM, 298 K) and BeStSel fitting (red). The
secondary-structure content estimated from the fitting is shown. (b) SEC-MALS elution profile of full-length XIAP (30 mM, 298 K). The refractive index
is shown in black; the calculated molecular mass of the XIAP dimer peak is shown in red. (c) 1H–15N HSQC NMR spectrum of the full-length XIAP
homodimer acquired at a dimer concentration of 80 mM at 700 MHz and 310 K. 70 amide cross-peaks are detected in the central region of the
spectrum, typical of unstructured proteins. No signals are detected from the folded domains owing to relaxation-induced broadening beyond detection.
missing loop atoms were randomly generated. The structure
was then minimized using a simulating-annealing protocol.
In the HADDOCK calculations the experimental restraints
(Rg = 38 A˚ from SAXS and the inter-cysteine distance
restraints Cys202–Cys202 = 38  6 A˚ and Cys351–Cys351 >
70 A˚ from EPR-DEER) were set as unambiguous restraints.
The Rg restraint weight was set to 0.01 in order to achieve a
broader structure distribution. C2 symmetry distance
restraints were also introduced. In order to preserve the BIR1
and RING homodimers, a set of unambiguous restraints
between CA atoms on opposite sides of the interface were
generated from the X-ray structures. In the first rigid-body
phase of HADDOCK calculations all of the structured parts
were fixed, which were then released in the final refinement.
The calculations were performed at the local PBS cluster at
CERM, Florence by calculating 40 000 structures in the rigid-
body step and 4000 in the second step. The deviation from the
experimental SAXS curve (2) was calculated for all of the
4000 resulting structures usingCRYSOL (Svergun et al., 1995).
3. Results and discussion
The integrated approach used in this study involved the
collection of several types of information for the structural
characterization of full-length XIAP. The CD spectrum indi-
cated that the purified protein is folded, and the secondary-
structure content was estimated by fitting the CD data
[Fig. 1(a)]. SEC-MALS experiments indicated that the protein
is monodisperse in solution and forms a homodimer of
approximately 115 kDa, consistent with the theoretical mole-
cular mass of 113.4 kDa for the dimeric form [Fig. 1(b)]. The
metallation state of the protein was determined by ICP-AES
and resulted in ten zinc ions per XIAP homodimer, indicating
that all of the binding sites are completely loaded with zinc.
In principle, the multidomain nature of XIAP could allow a
certain degree of relative flexibility of the single domains.
Therefore, heteronuclear NMR spectroscopy was used to
analyse the dynamic nature of the XIAP homodimer. Only a
small number of amide cross-peaks (70) were visible in the
central region of the 1H–15N HSQC spectrum of XIAP
[Fig. 1(c)]. These signals are likely to arise from the unstruc-
tured regions of the protein, i.e. the N-terminus and the linkers
between the domains. No signals typical of a folded protein
were detected, indicating that XIAP is sufficiently rigid and
reorients almost as a single dimeric form, thus slowing down
the molecular tumbling and causing broadening beyond
detection for the signals of the structured regions. NMR
experiments optimized for high-molecular-weight systems did
not provide additional signals, also owing to the low sample
concentration imposed by the aggregation propensity of XIAP
(data not shown). Further evidence of a rigid conformation
assumed by the dimeric state of full-length XIAP was
provided by EPR experiments. For this purpose, full-length
XIAP was labelled with MTSL either at Cys202 on the BIR2
domain (XIAP C202R1) or at Cys351 on the BIR3 domain
(XIAP C351R1). The X-band CW-EPR spectrum of XIAP
C202R1 at room temperature exhibits a line shape typical of
the presence of multi-motional components (Fig. 2, black
line). Its simulation indicated that the overall signal is domi-
nated by a broad component (C = 2.5 ns), specific for a rigid
structure, which accounts for 92% of the signal intensity
[Fig. 2(a), pink line], while a minor sharp component (C =
0.1 ns) typical of a very flexible confor-
mation accounts for 8% of the signal
[Fig. 2(a), blue line]. This indicates that
XIAP essentially has a rigid structure
around Cys202. Similar results were
obtained for XIAP C351R1: the CW-
EPR spectrum [Fig. 2(b), black line]
shows the presence of two minor sharp
components characteristic of very flex-
ible conformations, with spin-label
tumbling times of 0.1 and 0.5 ns
[Fig. 2(b), pink and green lines, respec-
tively], while most of the EPR signal
(84%) arises from a broader component
(C = 3.3 ns) [Fig. 2(b), pink line],
revealing that the protein also assumes
a rigid structure in the proximity of
Cys351. Overall, these findings confirm
that the XIAP homodimer in solution
adopts a relatively compact conforma-
tion.
To further describe the conformation
of XIAP, SAXS measurements were
performed which provided the overall
shape features of dimeric XIAP in
solution. Trace amounts of higher
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Figure 2
CW-EPR experiments on MTSL-labelled XIAP. X-band CW-EPR spectra at room temperature
and relative simulations of (a) XIAP C202–MTSL and (b) XIAP C351–MTSL are shown. The
experimental (blue) and simulated (red) spectra are overlaid. The sharp (blue/green) and broad
(magenta) components of each simulated spectrum are shown below. The relative contribution and
the calculated C are indicated for each component.
molecular-weight species were removed during the chroma-
tography step in the inline SEC-SAXS setup. In this way, the
scattering intensity data were measured solely for the pure
dimeric form. The radius of gyration (Rg) through the dimer
elution peak is consistent (36–38 A˚), suggesting that the solute
is indeed monodisperse. The final averaged SAXS profile of
dimeric full-length XIAP is shown in Fig. 3(a). The Guinier
plot of the SAXS data is linear, as expected for aggregate-free,
monodisperse systems, yielding an Rg of 38  0.6 A˚.
Compared with the expected molecular mass of 113.4 kDa, the
mass calculated by SAXS (Table 1) suggests that XIAP has a
relatively globular isotropic mass distribution. The a priori
shape classification of the SAXS data places XIAP in the
‘flat/compact’ regime. The corresponding p(r) versus r profile
[Fig. 3(c)] supports this observation as the distribution of
vector lengths is almost Gaussian, with a maximum particle
dimension (Dmax) of 130 A˚. Correspondingly, the peak
position in the dimensionless Kratky plot [Fig. 3(d)] shows a
behaviour typical of a globular protein (Receveur-Brechot &
Durand, 2012). The final structural parameters extracted from
the data, including volume and molecular-mass estimates, are
fully consistent with dimeric XIAP and with the SEC-MALS
results (Table 1). In addition, the ab initio low-resolution
structure indicated that the quaternary structure of the XIAP
homodimer displays a disc-like flat conformation [Fig. 3(b)].
We further defined the relative position of the single
domains in the XIAP homodimer by performing Q-band
EPR-DEER measurements on XIAP C202R1 and XIAP
C351R1. Since the protein is a homodimer, the values calcu-
lated from the DEER experiments correspond to the distances
between two spin-labelled cysteines
Cys202 (or Cys351) located one on each
monomer. For C202R1, the modulation
depth was estimated to be 0.012 and the
calculated distance distribution had a
single maximum at 38  6 A˚ (Fig. 4),
while for C351R1 the oscillation of the
echo-detected signal was not observed
(Supplementary Fig. S2), suggesting
that the two Cys351 residues of the
monomers are located farther than the
estimated upper limit of the DEER
experiment under our experimental
conditions (>70 A˚).
In order to obtain a family of models
of the XIAP dimer that would satisfy
the constraints derived from NMR (i.e.
the absence of fast-tumbling domains)
and EPR (i.e. the distances between
cysteine pairs), while simultaneously
minimizing the deviation from the
SAXS curve, an integrated approach
was devised. Specifically, HADDOCK
calculations were first run to generate
an ensemble of models that satisfy our
experimental constraints, followed by a
scoring based on the 2 from the SAXS
curve calculated with CRYSOL and a
final selection of representative models
by EOM. The initial input for
HADDOCK was constructed as an
O-shaped dimer (Supplementary Fig.
S3), in which the two monomers are
held together by the BIR1–BIR1 and
RING–RING interfaces and the linkers
are in an extended conformation, in
order to facilitate the convergence
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Figure 3
SAXS data, primary structural parameters and overall shape characteristics. (a) Averaged SEC-
SAXS profile of XIAP through the dimeric elution peak (black) and the corresponding fit against
the data from the best-fitting HADDOCK model (see Section 2; 2 = 1.5 with no systematic
deviation). (b) Ab initio bead-model reconstruction overlaid with the best-fitting HADDOCK
model. The most probable ab initiomodel determined with P2 symmetry is shown. The resolution of
the model was determined to be 34  3 A˚. (c) Distance distribution profile of XIAP. (d)
Dimensionless Kratky plot. The typical peak position for globular proteins (x = 31/2, y = 1.1) is
indicated.
Table 1
Structural parameters for XIAP from SAXS data.
Rg (from Guinier plot) (A˚) 38  0.6
Rg [from p(r) versus r] (A˚) 39  0.6
Dmax (A˚) 128
Vp (from Porod volume) (nm
3) 194
Vp (from DAMMIF ) (nm
3) 184
MM (from Porod volume) (kDa) 121
MM (from DATMOW ) (kDa) 120
MM (from Vc) (kDa) 118
MM (from DAMMIF ) (kDa) 92
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towards shapes compatible with the flat discoid obtained from
the ab initio modelling. The Rg from the SAXS data was used
as a loose energy constraint in HADDOCK, while the inter-
cysteine distances and the known dimer interfaces were
employed as unambiguous distance restraints. Owing to the
high degeneracy of the system, a large fraction of models of
the resulting ensemble satisfied the experimental constraints
(Supplementary Fig. S4). The ranking based solely on the
deviation from the SAXS curve shows that a few individual
models could adequately reproduce the curve, with the best-
fitting model fitting the data with 2 = 1.5 [Fig. 3(b)] and a total
of six structures fitting the data with a 2 below 2.1. Notably,
the Cys351–Cys351 distance distribution in a subset of models
that better reproduce the SAXS curve is shifted towards
longer distances, peaking at around 70 A˚ [Supplementary Fig.
S4(b)], therefore suggesting that the absence of modulation in
the DEER experiment indeed results from a long distance
instead of a broad distribution of shorter distances.
Flexibility analysis performed using EOM on the
HADDOCK ensemble further improved the fitting (2 = 1.4),
yielding a family of representative models that satisfy all of the
experimental constraints, being sufficiently compact to be
consistent with the slow tumbling rate observed by NMR
(Fig. 5 and Table 2). Notably, a similar flexibility analysis
performed on randomly generated conformers without taking
into account the DEER-derived distances resulted in a worse
fit of the SAXS curve (2 = 1.9; Supplementary Fig. S5 and
Table S1). It is also interesting that for random generation the
overall sizes of the EOM-selected models were significantly
smaller than the averages over the random pools [Supple-
mentary Figs. S5(c) and 5(d)], whereas for the HADDOCK
ensembles the selected models were generally more extended
than the pool averages [Figs. 5(c) and 5(d)]. These results
indicate that the integrated approach confined XIAP to a
narrower conformational space, allowing a more thorough
sampling of realistic conformers.
Taken together, from all of the evidence obtained XIAP is a
compact oblate-shaped dimer in solution. This finding has
important consequences when considering that XIAP has to
interact with many partners to exert its functions (Fig. 6). In
most cases such interactions take place between two copies of
the involved domains of XIAP and the relative partners, as is
the case for the BIR1–TAB (Lu et al., 2007) and BIR2–
caspase-3/7 complexes (Riedl et al., 2001; Scott et al., 2005),
which are dimeric in the crystallographic structure, and the
Figure 4
Q-band four-pulse DEER trace obtained for XIAP C202R1. (a) Experimental DEER trace (black) and estimated background (red). (b) DEER trace
after background correction (black) and the relative fitting obtained by Tikhonov regularization (red). (c) Calculated distance distribution. The
experimental data were treated using DeerAnalysis2016.
Table 2
Structural parameters of the models selected by EOM analysis of the
HADDOCK ensemble.
Models Rg (A˚) Dmax (A˚) Fraction
Cys202–Cys202
distance (A˚)
Cys351–Cys351
distance (A˚)
Model 1 40 144 45 43 102
Model 2 41 130 11 45 82
Model 3 41 135 33 42 77
Model 4 41 135 11 44 83
Ensemble 41 136
BIR2-BIR3–Smac/DIABLO complex, where it has been
proposed that a Smac/DIABLO tetramer binds two BIR2-
BIR3 pairs (Wu et al., 2000; Huang et al., 2003; Mastrangelo et
al., 2015). By comparing our
model [Fig. 6(a)] with previous
structural information, it can be
observed that while the BIR1–
TAB interaction is compatible
with a compact XIAP dimer, the
two BIR2 domains in complex
with caspase-3 are further apart
from each other [Cys202–Cys202
distance of 68.5 A˚; Fig. 6(b)] than
experimentally observed in the
XIAP dimer (Cys202–Cys202
distance of 38  6 A˚), suggesting
that the relative position of the
BIR2 domains must change to
allow binding to caspase-3/7.
Likewise, the proposed arrange-
ment of the two BIR2-BIR3 pairs
bound to the Smac/DIABLO
tetramer, although less clearly
defined, conceivably involves a
similar domain rearrangement
[Figs. 6(c) and 6(d)].
In our view, the fact that the
XIAP dimer must undergo a
conformational rearrangement to
allow binding to its partners is
highly relevant when seeking to
design more potent inhibitors of XIAP. Indeed, previous
efforts to develop IAP inhibitors revealed that dimeric ligands
showed higher potency with respect to their monomeric
analogues (Hennessy et al., 2013; LaCasse et al., 2008; Lecis et
al., 2012). Our results provide a plausible explanation for the
increased potency of these dimeric compounds, as the dimeric
compact structure of XIAP could allow the compounds to
bridge the two monomers, thus stabilizing the protein in the
caspase-free state.
4. Conclusions
Given the number of different pathways in which XIAP is
involved, it becomes necessary to determine whether they can
be affected or modulated by the three-dimensional organiza-
tion/architecture of the protein. This is especially relevant as
the BIR domains of XIAP are being closely studied as
potential anticancer drug targets (Fulda & Vucic, 2012). As is
often the case with multidomain proteins, the structures of the
single domains of XIAP have been relied upon for drug
screening and for investigating protein–protein interactions,
while the overall protein conformation has not been
accounted for. Here, by integrating complementary data from
different structural and biophysical techniques, we provided a
first low-resolution model of full-length XIAP and assessed
the degree of flexibility of the protein. In solution, XIAP
behaves homogenously and is present as a homodimer. Most
strikingly, our data indicate that the XIAP homodimer is
overall a rigid entity, despite the fact that the unstructured
research papers
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Figure 6
Schematic drawings showing the relative positions of the BIR2 and BIR3
domains and the distance between cysteines in the XIAP dimer and in
complexes with different partners. (a) XIAP homodimer based on a
representative model from theHADDOCK calculations performed in the
present study. (b) Two BIR2 domains in complex with a caspase-3 dimer
(PDB entry 1i3o; Riedl et al., 2001). (c) Two BIR3 domains in complex
with a Smac/DIABLO dimer (PDB entry 1g73; Wu et al., 2000). (d) Two
BIR2-BIR3 constructs in complex with a Smac/DIABLO tetramer based
on a SAXS-derived model (Mastrangelo et al., 2015). XIAP domains are
labelled with the initial letter of each name; inter-cysteine distances are
shown in (a), (b) and (c).
Figure 5
Flexibility assessment performed using EOM starting from the ensemble of HADDOCK models. (a) Fit
(red) against the SAXS data (black) with the EOM approach (2 = 1.4 with no systematic deviation). (b)
Representative models are shown as cartoons. The monomeric units are shown in red and blue, respectively.
(c, d) Distribution for the structural parametersDmax (c) and Rg (d) of selected models (red) compared with
those of the initial random pool (black).
N-terminus and the inter-domain linkers make up more than
20% of the overall sequence. This is suggested both by the
results of ab initio modelling and by the undetectability of the
folded domains within the XIAP dimer by solution NMR on
nondeuterated samples. The presence of a compact confor-
mation is confirmed by the family of models obtained by
integrating data from EPR-DEER and SAXS. Furthermore,
only 70 NMR signals from unfolded regions were detected,
i.e. about one half of the total expected unfolded residues,
suggesting that some of the inter-domain linkers could actually
adopt a defined, more rigid conformation within the overall
three-dimensional structure. Modelling the XIAP dimer based
on the integration of SAXS and EPR-DEER data was a
challenging task owing to the data being sparse compared with
the huge number of degrees of freedom of the system. Despite
this, our findings highlight the fact that XIAP assumes quite a
compact and rigid conformation and should not be treated
using simplistic ‘beads-on-a-string’ models when studying the
interactions with its many partners. Eventually, this notion
must be taken into account in the development of the next
generation of XIAP inhibitors.
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